Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2001
Business Overview: Curis is a biotechnology company developing regenerative therapeutics based on developmental biology, signaling pathways, and adult stem cells. The company operates through internal research and strategic alliances, including joint ventures with Elan International Services (Curis Newco) and collaborations with Micromet AG and Aegera Therapeutics.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2001 |
Nine Months Ended Sep 30, 2001 |
Nine Months Ended Sep 30, 2000 |
|---|---|---|---|
| Revenues | $287,915 | $739,718 | $743,813 |
| Net Loss | $(28,525,447) | $(65,609,684) | $(331,225,759) |
| Net Loss per Share (Basic/Diluted) | $(0.89) | $(2.08) | $(22.59) |
| Cash and Cash Equivalents | $48,395,466 | $48,395,466 | $20,625,579 |
| Total Current Assets | $64,062,679 | $64,062,679 | $77,077,483 |
| Total Debt (Current + Long-term) | $9,336,789 | $9,336,789 | $6,127,000 |
| Net Cash Used in Operating Activities | N/A | $(11,154,301) | $(14,248,046) |
Note: The 2000 Net Loss figures include a one-time $294.8 million charge for in-process research and development (IPR&D) related to the 2000 merger.
Material Changes vs. Prior Period
- Revenue: Revenue for the nine months ended Sept 30, 2001, remained flat at approximately $740,000 compared to $744,000 in the prior year. However, the composition shifted; 2001 revenue was driven by NIST grants ($661,000) and Stryker royalties ($79,000), whereas 2000 included $688,000 in license revenues from Stryker.
- Net Loss: The reported net loss for the nine months ended Sept 30, 2001, was $65.6 million, a significant improvement from the $331.2 million loss in the same period in 2000. The 2000 loss was heavily distorted by the $294.8 million IPR&D write-off from the merger of Ontogeny and Reprogenesis.
- Operating Expenses:
- R&D Expenses: Increased 127% to $22.9 million (nine months 2001) from $10.1 million (nine months 2000), primarily due to the consolidation of the three merged entities and increased operational scale.
- Stock-Based Compensation: Decreased to $9.2 million (nine months 2001) from $12.5 million (nine months 2000), largely due to the absence of one-time merger-related acceleration charges present in 2000.
- Amortization: Increased to $17.5 million (nine months 2001) from $8.6 million (nine months 2000) due to the amortization of goodwill and assembled workforce from the merger.
- Joint Venture Loss: A new line item, "Equity in loss from joint venture," appeared in 2001, totaling $12.7 million for the quarter and nine months. This includes a $12.0 million charge for the write-off of technology acquired for the Elan joint venture (Curis Newco).
Guidance, Outlook, and Risks
- Liquidity Outlook: As of September 30, 2001, the company held approximately $61.9 million in cash, cash equivalents, and marketable securities. Management anticipates these resources, combined with funds from the Elan joint venture, will sustain operations into the second quarter of 2003.
- Future Funding Needs: Beyond Q2 2003, the company expects to incur substantial costs for preclinical studies and clinical trials. Future funding will depend on royalty revenues (specifically from Stryker), collaborative arrangements, and additional equity or debt financings.
- Key Risks:
- Regulatory Approval: The business is materially dependent on the approval of OP-1 for commercial sale in the U.S. beyond its current limited Humanitarian Device Exemption. Failure to secure this approval would severely impact royalty revenue from Stryker.
- Financing: There is no assurance that additional financing will be available on favorable terms, and future equity issuances could result in dilution.
- Accounting Changes: The adoption of SFAS No. 142 on January 1, 2002, will cease the amortization of goodwill and assembled workforce, reducing annual operating expenses by approximately $11.5 million, though this will be offset by potential impairment charges.
- Unusual Items: The $12.0 million charge related to the Elan joint venture technology write-off is a non-recurring item specific to the formation of the new entity.
Investor Verification Checklist
- Stryker Royalty Dependency: Verify the status of OP-1 regulatory approvals and the volume of Stryker product sales, as these are the primary drivers of future royalty revenue.
- Elan Joint Venture Progress: Monitor the development milestones of Curis Newco (hedgehog signaling pathway) and the utilization of the $8.0 million convertible note facility with Elan.
- Cash Burn Rate: Confirm the company's ability to extend its cash runway beyond Q2 2003 given the high R&D spend ($22.9M for nine months) and lack of significant product revenue.
- Debt Obligations: Review the terms of the $4.05 million term loan with Fleet National Bank and the $2.0 million convertible note with Becton Dickinson, including interest rates and maturity dates.
- Goodwill Impairment: Assess the potential for goodwill impairment charges under the new SFAS No. 142 standard effective Jan 1, 2002, which could impact future earnings despite the reduction in amortization expense.